{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T14:15:25Z","timestamp":1781187325537,"version":"3.54.1"},"reference-count":25,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbiol&amp;#65533;Insights"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p>This review summarizes the literature on inhaled amphotericin B for invasive aspergillosis prophylaxis in patients with neutropenia secondary to hematologic malignancy treatment or stem cell transplant. Six trials, 2 randomized controlled and 4 with historical controls, were identified. Three inhaled amphotericin B deoxycholate trials found a reduced invasive aspergillosis incidence, 1 reaching statistical significance. Three inhaled liposomal amphotericin B trials demonstrated similar reductions with 2 finding statistical significance. Relative risk reductions for invasive aspergillosis were routinely 40-60%. Both formulations were without reported systemic or severe adverse effects. The most common adverse events were cough, bad taste, and nausea. Discontinuation rates ranged from 0-45%. The only randomized, placebo-controlled trial utilized inhaled liposomal amphotericin B reported a nearly 60% relative risk reduction.<\/jats:p>\n                  <jats:p>Inhaled liposomal amphotericin B 12.5 mg twice weekly is an alternative for invasive aspergillosis prophylaxis in high risk neutropenic patients with hematologic malignancies and stem cell transplant recipients when recommended azole agents are contraindicated or should not be used.<\/jats:p>","DOI":"10.1177\/1178636119869937","type":"journal-article","created":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T01:35:53Z","timestamp":1567042553000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":20,"title":["Inhaled Amphotericin B as Aspergillosis Prophylaxis in Hematologic Disease: An Update"],"prefix":"10.1177","volume":"12","author":[{"given":"Madison J","family":"Duckwall","sequence":"first","affiliation":[{"name":"Department of Pharmacy, INTEGRIS Baptist Medical Center, Oklahoma City, OK, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1351-7813","authenticated-orcid":false,"given":"Mark A","family":"Gales","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, INTEGRIS Baptist Medical Center, Oklahoma City, OK, USA"},{"name":"College of Pharmacy, Southwestern Oklahoma State University, Weatherford, OK, USA"},{"name":"Great Plains Family Medicine Residency, Oklahoma City, OK, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry J","family":"Gales","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, INTEGRIS Baptist Medical Center, Oklahoma City, OK, USA"},{"name":"College of Pharmacy, Southwestern Oklahoma State University, Weatherford, OK, USA"},{"name":"Great Plains Family Medicine Residency, Oklahoma City, OK, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,8,28]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw326."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.201802012."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S4244"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2016.040."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00374."},{"key":"e_1_3_2_7_2","unstructured":"AmBisome (amphotericin B liposome for injection) [product information]. San Dimas CA: Gilead Sciences; 2018."},{"key":"e_1_3_2_8_2","unstructured":"Amphotericin B (for injection) [product information]. Big Flats NY: X-Gen Pharmaceuticals; 2010."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12579."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.22856."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G477."},{"key":"e_1_3_2_12_2","first-page":"403","article-title":"Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytopenic patients","volume":"5","author":"Conneally E","year":"1990","unstructured":"Conneally E, Cafferkey MT, Daly PA, Keane CT, McCann SR. Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytopenic patients. Bone Marrow Transplant. 1990;5:403-406.","journal-title":"Bone Marrow Transplant"},{"key":"e_1_3_2_13_2","first-page":"3654","article-title":"Aerosolized amphotericin B inhalations as prophylaxis of invasive Aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial","volume":"93","author":"Schwartz S","year":"1999","unstructured":"Schwartz S, Behre G, Heinemann Vet al. Aerosolized amphotericin B inhalations as prophylaxis of invasive Aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood. 1999;93:3654-3661.","journal-title":"Blood"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2011.00661.x."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/586739."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000327802."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.02.023."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/588660."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01726364"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2008.09.001."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1309."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061098."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061094."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S124918."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s4058801500131."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.01.002."}],"container-title":["Microbiology Insights"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1178636119869937","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1178636119869937","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1178636119869937","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:53:02Z","timestamp":1767660782000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1178636119869937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":25,"alternative-id":["10.1177\/1178636119869937"],"URL":"https:\/\/doi.org\/10.1177\/1178636119869937","relation":{},"ISSN":["1178-6361","1178-6361"],"issn-type":[{"value":"1178-6361","type":"print"},{"value":"1178-6361","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]},"article-number":"1178636119869937"}}